Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03884829
Title A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Cyclacel Pharmaceuticals, Inc.
Indications

leukemia

myelodysplastic syndrome

Therapies

CYC140

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.